MRP8/14 in Rheumatoid Arthritis (RA)
MRP8/14 (S100A8/A9) is a laboratory biomarker that has been reported to be useful in a number of inflammatory disorders including Rheumatoid arthritis (Ehrchen et al.; leukocyte biol, 2009). Its release at sites of inflammation makes MRP8/14 a potent acute phase reactant. MRP8/14 has raised widespread interest in studies of acute and chronic disorders. Our assays for MRP8/14 allow for precise and sensitive measurement of this promising marker.
Rheumatoid Arthritis is a chronic disease that causes inflammation of joints and surrounding tissues often affecting other organs as well. It is an autoimmune disease characterized by relapsing inflammatory conditions in the joint cavities. Infiltrating neutrophils, among other cells play an important role in maintaining the inflammatory conditions. The protein complex S100A8 and S100A9 (also referred to as MRP8/14) is known for its pro-inflammatory actions and thus is a valid target for monitoring progression of disease and/or response to therapy (Frosch M. et al.; Arthritis Rheum, 2000). Both, the BÜHLMANN MRP8/14 ELISA and the point of care testing by Lateral Flow technology (Quantum Blue® sCAL) offer reliable and fast analysis of serum MRP8/14 in different settings.
Further indications (I): Acute Coronary Syndrome
As MRP8/14 is released by neutrophils and is thus involved in various inflammatory conditions, serum MRP8/14 also serves as marker for monitoring ongoing immune reactions. Elevated serum and plasma concentrations of MRP8/14 have recently been shown to play an important role in the management of patients suffering from cardio-vascular pathologies. The risk stratification and early diagnosis of patients with non-cardiac chest pain, stable coronary artery disease (CAD), or acute coronary syndromes is of utmost importance. The occurrence of elevated MRP8/14 in the systemic circulation prior to markers of myocardial necrosis makes it a prime candidate for the detection of unstable plaques and management of Acute Coronary Syndromes (Altwegg et al., European Heart Journal. 2007).
Further indications (II): Acute Transplant Rejection
Furthermore, MRP8/14 is a sensitive marker for the prediction of acute allograft rejection in kidney transplantation. MRP8/14 acts as an early indicator to monitor allograft rejection since it is released upon contact of neutrophils and monocytes with allograft tissue in the first weeks after transplantation (Burkhardt et al., J Am Soc Nephrol, 2001).
||Quantum Blue® sCAL
||BÜHLMANN MRP8/14 ELISA
|Time to Result
||15 min (approx.)
||2 h (approx.)
||20 μl Serum (1:10)
||<20 μl Serum/Plasma (1:100)
||0.5 – 10 μg/mL
||0.4 – 24 μg/mL
|| Quantum Blue® Reader 2nd generation